YONGTAI TECH.(SZ:002326)2022-12-06 09:52Group 1: Future Performance Expectations - The company expects to achieve a net profit of no less than 1.2 billion RMB over the next three years, with a potential increase to no less than 1.4 billion RMB if including performance commitments from Zhejiang Hand and Foshan Hand [1] - The actual controllers have committed to cover any shortfall in net profit if it does not reach 1.2 billion RMB from 2016 to 2018 [1] - The promised audited profit from Zhejiang Hand and Foshan Hand (calculated at 90% for Foshan) for the years 2016 to 2018 is no less than 224.8 million RMB [1] Group 2: 2016 Performance Forecast - The company forecasts a net profit attributable to shareholders of 167.15 million to 205.73 million RMB for the first three quarters of 2016, representing a growth of 30%-60% compared to the same period last year [2] - The primary reason for this growth is the rapid increase in sales revenue and favorable conditions for product delivery and new orders [2] Group 3: Project Developments - The subsidiary Yongtai High-tech plans to invest in a project to produce 6,000 tons of lithium hexafluorophosphate and 2,000 tons of new lithium salts, with an initial investment of 387.6 million RMB [2] - The first phase of the project will have a production capacity of 3,000 tons of lithium hexafluorophosphate and 1,000 tons of new lithium salts, expected to generate an additional annual revenue of 940 million RMB and a net profit of 93.31 million RMB once fully operational [2] Group 4: Technological Advancements - The wholly-owned subsidiary Zhejiang Yongtai Pharmaceutical has acquired production technology for Nevirapine, which is used to treat HIV-1 infections [2] - This acquisition will facilitate the advancement of domestic raw material drug GMP certification and promote the internationalization of formulations [2]